Interim report Q1 2025

Curasight’s CEO Ulrich Krasilnikoff comments:

“During the first quarter of 2025 we have worked hard to secure the necessary financial resources to deliver on our strategy of developing our diagnostic and therapeutic platforms uTRACE® and uTREAT®in parallel. Despite the ongoing macroeconomic challenges, we were able to announce a rights issue by the end of first quarter, which aims to raise approximately DKK 100 million of new capital. Approximately DKK 65 million in funding is already in place, with DKK 47 million confirmed through pre-subscriptions and guarantee commitments — including from two new strategic shareholders, our uTRACE partner Curium and the institutional investor Pentwater, who together account for nearly half of the secured capital in the rights issue. We expect 2025 to be another eventful year for the company with a number of important clinical milestones imminent value inflection points in relation to clinical development, as the strengthened financial base will ensure completion of the phase II study in prostate cancer by the end of 2025. Similarly, the new capital resources will also ensure the completion of a phase 1 study in aggressive brain cancer, making Curasight also a therapeutic company with proof-of-concept in uTREAT.”

Q1 (2025-01-01 – 2025-03-31)

• Gross loss amounted to kDKK -4,699 (kDKK -7,385)
• Operating loss amounted to kDKK -6,209 (kDKK -9,376)
• Loss before tax amounted to kDKK -6,579 (kDKK -9,367)
• Loss for the period amounted to kDKK -5,204 (kDKK -7,992)
• Total assets amounted to kDKK 17,660 (kDKK 27,574)
• Equity ratio amounted to 14,2% (84,8%)
• Earnings per share amounted to DKK -0,25 (DKK -0,40)

Numbers in parenthesis are the numbers from the same period in 2023.